Key Highlights

● Eli Lilly fell 2.32% to $1,382.75, then fell 2.29% to $1,351.12.

● Third-quarter Revenue rose 39% to $24.4 billion on Mounjaro and Zepbound.

● Lilly raised 2026 revenue guidance to $91 billion to $92 billion.

● Shares trade near 45 times trailing earnings, among the richest megacap multiples.

What makes Eli Lilly's (NYSE:LLY) 2.32% decline on Wednesday notable is less the size of the move than the lack of a company-specific trigger. The $1.3 trillion drugmaker closed at $1,382.75, down from $1,415.55 the day before. Volume was 2.88 million shares, close to normal, with relative volume of 0.91. Lilly makes the list of the most active US stocks mainly because of its share price: at more than $1,300 a share, its dollar volume is large even on an ordinary day. No new Lilly announcement, analyst downgrade or drug news was found to explain the drop. It came on a weak day for health care and for the Dow, as investors sold insurers on a federal Medicare proposal and digested hawkish signals from the Federal Reserve. On Thursday, Nov. 19, the stock fell another 2.29% to $1,351.12.

A tough day for health care

The biggest story in the sector was a proposed rule from the Centers for Medicare & Medicaid Services, released Nov. 16. It would expand audits of Medicare Advantage insurers and could recover about $9 billion a year in overpayments. Insurers bore the brunt. UnitedHealth (NYSE:UNH) fell 10.21%, Humana (NYSE:HUM) 12.98%, Elevance (NYSE:ELV) 7.63% and Centene (NYSE:CNC) 7.03% on Wednesday. The rule targets insurers rather than drugmakers, and nothing tied Lilly's move directly to it. But the selloff weighed on health care sentiment broadly, and the Dow fell 1.11% while the S&P 500 slipped 0.23%.

The macro backdrop was also unfriendly to richly valued stocks. Minutes from the Fed's last meeting showed that almost all officials judged further rate increases would likely be appropriate, and one Fed governor suggested the Fed might need to act more aggressively on inflation. The dollar hit a 19-month high. Higher rates tend to weigh most on companies whose valuations depend on Earnings far in the future.

What Lilly does

Lilly is a global pharmaceutical company best known for tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for obesity. It also sells Foundayo, a once-daily oral GLP-1 pill, along with drugs in cancer, immunology and neuroscience, including Jaypirca, Ebglyss and the Alzheimer's treatment Kisunla. Its pipeline includes retatrutide, a next-generation obesity drug, and EloraTZP, a combination of eloralintide and tirzepatide.

Recent results and guidance

Lilly's third quarter, reported Oct. 29, was exceptionally strong. Revenue rose 39% to $24.4 billion, about 10% above the $22.11 billion consensus. Mounjaro sales grew 65% to $10.7 billion and Zepbound rose 49% to $5.4 billion. Foundayo, still early in its launch, brought in $184 million, up from $98 million the previous quarter. Adjusted earnings were $7.48 per share against a consensus of $5.38. Reported earnings were $7.22 per share, up 16%. Both reported and adjusted earnings included $4.57 per share of charges for acquired research and development.

Growth was broad. US revenue rose 34% to $15.1 billion, while revenue outside the US jumped 47% to $9.3 billion. The quarter also benefited from $410 million in Jardiance milestone payments and favorable adjustments to US rebate and discount estimates, which flattered the headline beat. Newer products are adding up as well: Jaypirca brought in $228 million, Ebglyss $202 million, Kisunla $193 million, Omvoh $114 million and Inluriyo $73 million. The shares rose about 4% in premarket trading after the report and were then up 20.8% for the year.

Lilly raised its 2026 revenue guidance to $91 billion to $92 billion, from $85 billion to $87 billion. It trimmed adjusted earnings guidance to $35.00 to $36.00 per share, from $35.50 to $36.50, because the Acquisition charges more than offset stronger underlying growth. "Lilly had another strong quarter, exceeding our prior expectations and allowing us to raise our full-year outlook," said Chair and CEO David A. Ricks.

New data at ObesityWeek

Lilly used ObesityWeek, held Nov. 14 to 17 in Washington, D.C., to present new data. In a Phase 2 trial, adults with obesity or overweight and type 2 diabetes taking EloraTZP lost up to an average of 23.3% of their body weight, or 54.1 pounds, at 48 weeks. A1C, a measure of blood sugar, fell by up to an average of 2.9 points, and up to 77% of participants reached normal blood sugar levels.

Phase 3 trials of retatrutide showed sharp reductions in sleep apnea events, with breathing disruptions per hour falling by up to 60.6% at 80 weeks in the TRIUMPH-1 study. Knee osteoarthritis pain scores fell by up to 75.8% at 68 weeks in TRIUMPH-4. A survey of Foundayo users found that 96% to 98% considered the pill simple, convenient and easy to use. The data came before Wednesday's decline, and the stock's drop does not appear to reflect any disappointment with the results.

Valuation

At a trailing P/E of 45.43, Lilly is one of the most expensive mega-cap stocks in the most-active list. It sits close to Broadcom (NASDAQ:AVGO) at 45.20 and Walmart (NASDAQ:WMT) at 46.14, and far above UnitedHealth at 19.97 and Alphabet (NASDAQ:GOOGL) at 14.75. Investors are paying for growth: revenue grew 39% last quarter, and guidance implies sales of more than $90 billion this year.

The bull case

Supporters see years of growth ahead in obesity and diabetes. Jefferies raised its price target to $1,700 from $1,610 on Nov. 9, the highest on Wall Street at the time. It argued that the market for obesity drugs outside the US could eventually be at least as large as the domestic one, with roughly twice as many potential patients. Jefferies also said obesity treatment is "consumer-driven," with patients weighing efficacy, tolerability and convenience as well as price. The firm also cited possible higher realized prices as patients move to higher doses, better margins abroad and favorable Economics for oral treatments. A deep pipeline and an oral option in Foundayo give Lilly several ways to defend its lead.

The bear case

The main risk is the valuation itself. A stock priced at more than 45 times trailing earnings has little room for setbacks, whether from pricing pressure, competition or slower uptake abroad. Jefferies itself expects international adoption to take longer than in the US. Lilly also depends heavily on a single molecule, tirzepatide, and its acquisitions have weighed on reported earnings. A Fed that keeps raising rates would add pressure on high-multiple stocks.

What to watch next

Without a clear company-specific catalyst, Lilly's next moves may track the health care sector and interest rates. Investors will watch Fed commentary ahead of its next meeting, Foundayo prescription trends, further retatrutide readouts and any changes in US drug pricing policy. Lilly's fourth-quarter results and 2027 guidance, expected early next year, will be the next major company event.